COSTA MESA, Calif.--(BUSINESS WIRE)--July 18, 2006--Valeant Pharmaceuticals International (NYSE:VRX - News) today announced the U.S. launch of Zelapar® (selegiline HCl) Orally Disintegrating Tablets. Zelapar is the first Parkinson's disease treatment to use a novel oral delivery system called Zydis® Technology, which allows the tablets to dissolve within seconds in the mouth and deliver more active drug at a lower dose. Zelapar will be available in pharmacies nationwide by July 19, 2006.
